📖
Part of the Complete GLP-1 Guide 2026 — the central resource for accessing, comparing, and understanding GLP-1 medications.
One of the most common questions from patients starting GLP-1 therapy is simply: "What should I actually expect?" The answer varies by individual, but the clinical trial data from the STEP and SURMOUNT programs provides a reliable framework for what most patients experience — and when. Understanding this timeline helps patients stay the course through the challenging early weeks and recognize when results are on track versus when something may need adjustment.
The clinical timeline in brief
Weeks 1–4: side effects are most prominent, weight loss is minimal. Weeks 4–16: dose escalation continues, appetite suppression becomes noticeable. Weeks 16–20: maintenance dose reached, most GI symptoms resolved. Weeks 20–68: sustained weight loss, with average results of 14.9% by week 68 in the STEP 1 trial.1
Weeks 1–4 — Starting Dose (0.25 mg)
Side effects most prominent. Weight loss minimal.
The 0.25 mg starting dose is a tolerability dose, not a therapeutic dose. Nausea, mild fatigue, and reduced appetite begin. Most patients lose 1–3 lbs during this phase — do not judge the medication's effectiveness yet. Focus on tolerating the side effects and building injection habits.
Weeks 5–8 — 0.5 mg Dose
Appetite suppression becomes noticeable. First significant weight loss.
At 0.5 mg, most patients begin experiencing meaningful reduction in appetite and portion sizes. Average weight loss in STEP 1 participants at approximately 8 weeks was around 4–5% of body weight. Nausea typically improves but may recur briefly at each dose step. Many patients report "food noise" (intrusive thoughts about food) beginning to quiet.
Weeks 9–16 — 1 mg then 1.7 mg
Significant weight loss underway. GI symptoms stabilizing.
This is typically when patients see the most dramatic early results. Appetite is substantially suppressed, eating patterns have shifted, and weight loss is consistent. Clinical trial data shows approximately 8–10% weight loss by week 16 in high-adherent participants. Constipation may become more prominent at higher doses — adequate hydration and fiber are important.
Weeks 17–20 — Reaching 2.4 mg Maintenance
Full therapeutic dose reached. Steady state begins.
At 2.4 mg, semaglutide reaches steady-state plasma concentrations after 4–5 doses. Most GI side effects have resolved by this point for the majority of patients. Appetite suppression is at its maximal pharmacological effect. Patients who have reached maintenance dose are typically experiencing 10–12% weight loss.
Weeks 20–68 — Sustained Loss Phase
Continued weight loss. Metabolic improvements compound.
The STEP 1 trial primary endpoint of 68 weeks demonstrated 14.9% mean weight loss. Weight loss typically continues through week 68 in clinical trials, though the rate slows as a new homeostatic set point is approached. Cardiometabolic improvements — blood pressure, lipids, blood glucose — continue to accrue throughout this phase.
Find a GLP-1 option matched to your state and budget in 60 seconds.
Get My Match →
What the Clinical Trial Data Shows at Key Timepoints
| Timepoint | Mean Weight Loss (Semaglutide 2.4 mg) | % Achieving ≥5% Loss |
|---|
| Week 20 | ~10–11% | ~75% |
| Week 68 (primary endpoint) | 14.9% | 86.4% |
| Week 68 (≥10% loss) | 69.1% of participants | — |
| Week 68 (≥15% loss) | 50.5% of participants | — |
| 2-year extension (STEP 5) | 15.2% | 77.1% |
What to Do If You Are Not Seeing Results
If you are at maintenance dose (2.4 mg) for at least 12 weeks and have lost less than 5% of body weight, discuss with your prescriber whether continued treatment is appropriate. The STEP 1 protocol used this threshold as a basis for evaluating treatment response. Some patients are non-responders, and early identification prevents sustained cost without benefit.
More commonly, "lack of results" reflects one of the 7 correctable mistakes covered in our GLP-1 optimization guide. Review that before concluding the medication is not working for you.